Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
26-week randomized trial of tideglusib in mild-to-moderate Alzheimer's disease
2010-023322-21Phase 2Completed
- Sponsor
- Noscira S.A.
- Start
- Nov 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tideglusib in Alzheimer's disease (AD) (4 arms), sponsored by Noscira S.A. Primary endpoint: Primary efficacy endpoint. Started Nov 2010; status: completed.
02
Drugs
tideglusib
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2010-023322-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023322-21.